MTD:NYE-Mettler-Toledo International Inc. (USD)

EQUITY | Diagnostics & Research | New York Stock Exchange

Last Closing

USD 1479.3

Change

-22.48 (-1.50)%

Market Cap

USD 10.87B

Volume

0.09M

Analyst Target

USD 865.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Mettler-Toledo International Inc is engaged in the supply of precision instruments and services. It is a provider of weighing instruments for use in laboratory, industrial and food retailing applications.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-23 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
TMO Thermo Fisher Scientific Inc

N/A

USD 219.83B
DHR Danaher Corporation

N/A

USD 191.36B
IQV IQVIA Holdings Inc

N/A

USD 39.94B
A Agilent Technologies Inc

N/A

USD 37.89B
WAT Waters Corporation

N/A

USD 17.83B
LH Laboratory Corporation of Amer..

N/A

USD 16.74B
DGX Quest Diagnostics Incorporated

N/A

USD 15.68B
RVTY Revvity Inc.

N/A

USD 13.69B
CRL Charles River Laboratories

N/A

USD 10.94B
QGEN Qiagen NV

N/A

USD 9.95B

ETFs Containing MTD

MCSE Martin Currie Sustainable.. 4.98 % 0.00 %

N/A

USD 0.03B
EPRE 4.58 % 0.00 %

N/A

N/A
GDOC Goldman Sachs ETF Trust 3.45 % 0.00 %

N/A

USD 0.03B
GLGG:LSE L&G Clean Water UCITS ETF 2.31 % 0.00 %

N/A

USD 0.46B
GLUG:LSE L&G Clean Water UCITS ETF 2.31 % 0.00 %

N/A

USD 0.46B
POWA Invesco Bloomberg Pricing.. 2.28 % 0.00 %

N/A

USD 0.20B
GLUG:SW L&G Clean Water UCITS ETF.. 2.20 % 0.00 %

N/A

USD 0.45B
XMLC:F L&G Clean Water UCITS ETF 2.20 % 0.00 %

N/A

USD 0.42B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

N/A

USD 1.15B
HECO 0.00 % 0.95 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 7.34B
QRI:CA 0.00 % 1.06 %

N/A

N/A
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

N/A

CAD 0.05B
YXM.B:CA 0.00 % 0.69 %

N/A

N/A
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A
BMED BlackRock Future Health E.. 0.00 % 0.00 %

N/A

USD 4.21M
DWEQ 0.00 % 0.00 %

N/A

N/A
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

USD 5.63M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

USD 5.63M
PFUT Putnam Sustainable Future.. 0.00 % 0.00 %

N/A

USD 0.26B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.96% 100% F 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.96% 100% F 91% A-
Trailing 12 Months  
Capital Gain 12.33% 62% D 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.33% 62% D 47% F
Trailing 5 Years  
Capital Gain 102.97% 82% B 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 102.97% 82% B 84% B
Average Annual (5 Year Horizon)  
Capital Gain 17.32% 85% B 82% B
Dividend Return 17.32% 77% C+ 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.32% 31% F 35% F
Risk Adjusted Return 55.30% 69% C- 78% C+
Market Capitalization 10.87B 69% C- 92% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 30.90 42% 14%
Price/Book Ratio 3,980.99 8% 0%
Price / Cash Flow Ratio 33.67 23% 8%
Price/Free Cash Flow Ratio 24.72 23% 9%
Management Effectiveness  
Return on Equity 29.51% 92% 91%
Return on Invested Capital 48.71% 93% 97%
Return on Assets 20.32% 100% 99%
Debt to Equity Ratio -1,259.60% 100% 99%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.